We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Schumer’s Completely Unhelpful Approach to Curbing Drug Shortages
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > Schumer’s Completely Unhelpful Approach to Curbing Drug Shortages
BusinessNewsPublic Health

Schumer’s Completely Unhelpful Approach to Curbing Drug Shortages

DavidEWilliams
DavidEWilliams
Share
3 Min Read
SHARE

Shortages of lifesaving drugs have been rising toward crisis levels in recent years. As a result some hospitals have been forced to delay treatment, substitute other drugs, or pay high prices to secure supplies from distributors. Michelle Hudspedth, pediatric hematology and oncology chief at the Medical University of South Carolina explains that federal policy is largely responsible for the shortages. In particular it’s hard for the drug companies to make money.

Shortages of lifesaving drugs have been rising toward crisis levels in recent years. As a result some hospitals have been forced to delay treatment, substitute other drugs, or pay high prices to secure supplies from distributors. Michelle Hudspedth, pediatric hematology and oncology chief at the Medical University of South Carolina explains that federal policy is largely responsible for the shortages. In particular it’s hard for the drug companies to make money. From California Healthline:

Hudspeth identified the Medicare Modernization Act of 2003 as the main reason for drug shortages, as it shifted the reimbursement rate from a percentage of average wholesale pricing to the average selling price, including all discounts and rebates.

She said, “Generic prices are driven down by market competition, and the current model under the MMA makes it difficult for companies to raise prices more than 6% per year.” Hudspeth added, “Product margins have fallen significantly for many generic drugs, leaving companies with little incentive to continue manufacturing the drug or to increase production” (Modern Healthcare, 11/30)

More Read

Hospital Training Using Virtual World and Avatars
Healthcare Software Testing for Seamless Stakeholders Experience
Is The Future Of Injectable Drug Delivery In Needle-Free Devices?
Expanding Insurance May Not Mean Long Lines and Trouble Seeing the Doctor
Physician-Led Advocacy Group Strives for Diversity among Its Profession

Problems in manufacturing plants are also playing a role, as sterile drugs for injection/infusion are notoriously hard to produce.

Now Senator Charles Schumer of New York is proposing a headline-grabbing but wrong headed idea: to make it illegal for drug distributors to engage in “price gouging” when they sell medications. The law would be backed up with penalties of up to $500 million per case. Said Schumer:

“Forcing hospitals to buy life-saving medications at outrageously inflated prices is unquestionably unethical, and with this legislation it would be illegal, too.”

Schumer should really be focusing on the root causes of the problem instead of blaming a seller for engaging in a market clearing transaction. The seller isn’t “forcing” a hospital to buy any more than the hospital is “forcing” the seller to sell. If anything, Schumer’s law would make things worse by eliminating the incentive for distributors to hunt down pockets of excess supply and scaring buyers and sellers away from pursuing transactions to avoid getting tangled up in a legal case.


TAGGED:drug shortagespharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Clinical-trial operations editorial illustration combining healthcare and technology: country-specif
Clinical Study Operations Across Eastern European Research Markets
Health
October 31, 2026
Flat editorial illustration: A health-editorial scene of a first pain-management visit, bringing together attentive consultation,
What to Expect at Your First Pain Management Appointment
Therapies Wellness
October 29, 2026
Flat editorial illustration: The core relationship is medication-only coverage versus coverage for a supervised clinical program.
Medical Weight Loss as a Workplace Benefit: The Questions I Would Want Asked
Weight Loss Wellness
October 29, 2026
Common Questions About Tirzepatide and Medical Monitoring -- AI-generated illustration
Common Questions About Tirzepatide and Medical Monitoring
Health
October 26, 2026

You Might also Like

New Ways to Incorporate Video into Your Healthcare Marketing Campaign

July 21, 2014
healthcare IT
BusinesseHealthHospital AdministrationPolicy & LawTechnology

5 Questions with Dan Haley, VP of Government and Regulatory Affairs at athenahealth

April 17, 2013
Dr. Mike Sevilla
BusinessGlobal HealthcareSocial Media

Dr. Anonymous: Blogger, Podcaster, Early Adopter [PODCAST]

September 29, 2014
medical school
BusinessMedical Education

First U.S. Insurer to Build Medical School

April 14, 2016
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?